STAT+: Two more drugmakers join TrumpRx
Why it matters: Earlier heart prevention and expanded drug collaborations could save lives, but funding and reimbursement roadblocks threaten progress.
- TrumpRx welcomes two more pharmaceutical partners, boosting its pipeline for ALS and other neurodegenerative therapies (STAT+).
- American Heart Association and other cardiology societies push cholesterol screening to age 30, shifting prevention earlier in life (STAT+).
- ALS advocacy groups caution that federal funding reductions could cripple ongoing research and delay new treatments (STAT+).
- Medical device manufacturers report that even after FDA clearance, Medicare reimbursement can take years, slowing patient access (STAT+).
New cardiology guidelines urge cholesterol screening and treatment starting at age 30, while TrumpRx expands its roster with two additional drugmakers. At the same time, ALS advocates warn that looming funding cuts could stall research, and device makers face years‑long waits for Medicare coverage after FDA approval.
